
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
BiotechTV - News
00:00
Distinct CBP/p300 Inhibitor Chemistry
Stefanie Fluckiger-Mangual compares Tolremo’s phenotypically discovered CBP/p300 bromodomain inhibitor with CellCentric’s different chemistry.
Play episode from 01:38
Transcript


